The Tolerability of Mirtazapine Augmentation in Schizophrenic Patients Treated with Risperidone: A Preliminary Randomized Placebo-controlled Trial
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Some patients with schizophrenia may need mirtazapine augmentation to improve negative and cognitive symptoms. However there have been a few studies about the tolerability of mirtazapine augmentation to antipsychotics such as akathisia,extrapyramydal symptoms, weight gain, and body mass index (BMI). Methods: This study was an eight-week double-blind, randomized controlled trial (RCT) of mirtazapine augmentation to risperidone. Twenty-one stabilized participants diagnosed with schizophrenia and undergoing treatment with risperidone were randomized to adjunctive treatment with mirtazapine (15 mg/day for the first two weeks, 30 mg/day for the next six weeks) or placebo. Eleven patients were assigned to the mirtazapine group, and nine patients were given placebo. Results: There was no significant difference between the mirtazapine and placebo groups with respect to Barnes Akathisia rating Scale (BAS) and Sympsom-Angus Scale (SAS). However, the mirtazapine group exhibited a statistically significant increase in weight and BMI (p＜0.05). Conclusion: These results suggest that mirtazapine augmentation can be tolerable in schizophrenic patients treated with risperidone;however, we should pay attention to the weight gain with mirtazapine. Our results should be replicated in a large-scale lengthy trial.
Abstract
Objective: Some patients with schizophrenia may need mirtazapine augmentation to improve negative and cognitive symptoms. However there have been a few studies about the tolerability of mirtazapine augmentation to antipsychotics such as akathisia,extrapyramydal symptoms, weight gain, and body mass index (BMI). Methods: This study was an eight-week double-blind, randomized controlled trial (RCT) of mirtazapine augmentation to risperidone. Twenty-one stabilized participants diagnosed with schizophrenia and undergoing treatment with risperidone were randomized to adjunctive treatment with mirtazapine (15 mg/day for the first two weeks, 30 mg/day for the next six weeks) or placebo. Eleven patients were assigned to the mirtazapine group, and nine patients were given placebo. Results: There was no significant difference between the mirtazapine and placebo groups with respect to Barnes Akathisia rating Scale (BAS) and Sympsom-Angus Scale (SAS). However, the mirtazapine group exhibited a statistically significant increase in weight and BMI (p＜0.05). Conclusion: These results suggest that mirtazapine augmentation can be tolerable in schizophrenic patients treated with risperidone;however, we should pay attention to the weight gain with mirtazapine. Our results should be replicated in a large-scale lengthy trial.
참고문헌 (19)
- Kasper S, "Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data", Int Clin Psychopharmacol, 10(Suppl 4), pp.25~35 (1995)
- Montgomery SA, "Safety of mirtazapine: a review", Int Clin Psychopharmacol, 10(Suppl 4), pp.37~45 (1995)
- Berk M, "Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial", Hum Psychopharmacol, 24, pp.233~238 (2009)
- Joffe G, "Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial", Schizophr Res, 108, pp.245~251 (2009)
- 최태규, "Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial", Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(1), pp.208~211, Elsevier BV
- Abbasi SH, "The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: adouble-blind randomized placebo-controlled trial", SchizophrRes, 116, pp.101~106 (2010)
- Hieber R, "Role of mirtazapine in the treatment of antipsychotic-induced akathisia", Ann Pharmacother, 42, pp.841~846 (2008)
- Poyurovsky M, "Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study", J Clin Psychopharmacol, 23, pp.305~308 (2003)
- Spitzer RL, "The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description", Arch Gen Psychiatry, 49, pp.624~629 (1992)
- Guy W, "Patient assessment in clinical trials", Prog Neuropsychopharmacol Biol Psychiatry, 6, pp.601~606 (1982)
- Barnes TR, "The Barnes Akathisia Rating Scale--revisited", J Psychopharmacol, 17, pp.365~370 (2003)
- Simpson GM, "A rating scale for extrapyramidal side effects", Acta Psychiatr Scand Suppl, 212, pp.11~19 (1970)
- Sachdev P, "A rating scale for acute drug-induced akathisia: development, reliability, and validity", Biol Psychiatry, 35, pp.263~271 (1994)
- Owens DGC, (1999), Cambridge University Press
- Kay SR, "The positive and negative syndrome scale (PANSS) for schizophrenia", Schizophr Bull, 13, pp.267~276 (1987)
- Vanderkooy JD, "Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine", Can J Psychiatry, 47, pp.174~180 (2002)
- Ranjan S, "Atypical antipsychotic-induced akathisia with depression: therapeutic role of mirtazapine", Ann Pharmacother, 40, pp.771~774 (2006)
- Berendsen HH, "Mirtazapine enhances the effect of haloperidol on apomorphine-induced climbing behaviour in mice and attenuates haloperidolinduced catalepsy in rats", Psychopharmacology (Berl), 135, pp.284~289 (1998)
- Ackerman S, "Bodyweight gain induced by psychotropic drugs. Incidence, mechanisms and management", CNS Drugs, 9, pp.135~151 (1998)